S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
NASDAQ:VCEL

Vericel (VCEL) Stock Price, News & Analysis

$47.90
-0.82 (-1.68%)
(As of 04/12/2024 ET)
Today's Range
$46.94
$48.93
50-Day Range
$43.22
$52.90
52-Week Range
$29.24
$53.05
Volume
301,434 shs
Average Volume
486,116 shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.40

Vericel MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.1% Downside
$46.40 Price Target
Short Interest
Bearish
9.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Vericel in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.76 M Sold Last Quarter
Proj. Earnings Growth
455.56%
From $0.09 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.62 out of 5 stars

Medical Sector

878th out of 925 stocks

Biological Products, Except Diagnostic Industry

149th out of 153 stocks

VCEL stock logo

About Vericel Stock (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

VCEL Stock Price History

VCEL Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Analyst Scoreboard: 5 Ratings For Vericel
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
VCEL Oct 2024 50.000 call
A Closer Look at 4 Analyst Recommendations For Vericel
Vericel Corporation (VCEL)
CRSP Mar 2024 79.000 put
CRSP Mar 2024 72.000 put
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/14/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VCEL
Employees
314
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$46.40
High Stock Price Target
$54.00
Low Stock Price Target
$39.00
Potential Upside/Downside
-3.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-3,180,000.00
Pretax Margin
-1.20%

Debt

Sales & Book Value

Annual Sales
$197.52 million
Cash Flow
$0.02 per share
Book Value
$4.73 per share

Miscellaneous

Free Float
45,864,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
1.71

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


VCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price target for 2024?

6 brokerages have issued 1 year price targets for Vericel's stock. Their VCEL share price targets range from $39.00 to $54.00. On average, they predict the company's share price to reach $46.40 in the next twelve months. This suggests that the stock has a possible downside of 3.1%.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2024?

Vericel's stock was trading at $35.61 at the beginning of the year. Since then, VCEL shares have increased by 34.5% and is now trading at $47.90.
View the best growth stocks for 2024 here
.

Are investors shorting Vericel?

Vericel saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily volume of 536,800 shares, the days-to-cover ratio is currently 8.2 days.
View Vericel's Short Interest
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.08. The biotechnology company earned $65 million during the quarter, compared to analysts' expectations of $64.28 million. Vericel had a negative trailing twelve-month return on equity of 1.55% and a negative net margin of 1.61%. The company's quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 earnings per share.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Who are Vericel's major shareholders?

Vericel's stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (1.73%), Los Angeles Capital Management LLC (0.06%), Park Avenue Securities LLC (0.01%) and Juncture Wealth Strategies LLC (0.01%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VCEL) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners